Cefpimizole | Antibiotic | CAS# 84880-03-5

MedKoo Cat#: 571408 | Name: Cefpimizole

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefpimizole is a broad-spectrum caphalosporin antibiotic. It shows limited side effects and high efficacy. Overall, cefpimizole exhibited limited activity against gram-positive cocci and members of the family Enterobacteriaceae as compared with the other cephalosporins tested. The activity of cefpimizole against Pseudomonas aeruginosa was similar to that of cefoperazone and mezlocillin (90% MIC, 32 micrograms/ml) but poorer than that of ceftazidime (90% MIC, 8 micrograms/ml). Cefpimizole appears to have no in vitro advantage over the cephalosporins with which it was compared.

Chemical Structure

Cefpimizole

CAS#84880-03-5 (free base)

Theoretical Analysis

MedKoo Cat#: 571408

Name: Cefpimizole

CAS#: 84880-03-5 (free base)

Chemical Formula: C28H26N6O10S2

Exact Mass: 670.1152

Molecular Weight: 670.67

Elemental Analysis: C, 50.15; H, 3.91; N, 12.53; O, 23.86; S, 9.56

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

85287-61-2 (sodium) 84880-03-5 (free base)

Synonym

Cefpimizole; AC 1370; A-1370; AC1370; U 63196; U-63196; U63196; U-63196E; U 63196E; U63196E;

IUPAC/Chemical Name

Pyridinium, 1-((2-carboxy-7-(((((5-carboxy-1H-imidazol-4-yl)carbonyl)amino)phenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)-, hydroxide, inner salt, (6R-(6alpha,7beta(R*)))-

InChi Key

LNZMRLHZGOBKAN-PSHWQTJJSA-N

InChi Code

InChI=1S/C28H26N6O10S2/c35-23(18(16-4-2-1-3-5-16)31-24(36)19-20(27(38)39)30-14-29-19)32-21-25(37)34-22(28(40)41)17(13-45-26(21)34)12-33-9-6-15(7-10-33)8-11-46(42,43)44/h1-7,9-10,14,18,21,26H,8,11-13H2,(H5-,29,30,31,32,35,36,38,39,40,41,42,43,44)/t18?,21-,26-/m0/s1

SMILES Code

O=S(CCC1=CC=[N+](CC(CS[C@@]2([H])[C@H]3NC(C(NC(C4=C(C(O)=O)NC=N4)=O)C5=CC=CC=C5)=O)=C(C(O)=O)N2C3=O)C=C1)([O-])=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 670.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Xu H, Xu R, Wang X, Liang Q, Zhang L, Liu J, Wei J, Lu Y, Yu D. Co-infections of Aeromonas veronii and Nocardia seriolae in largemouth bass (Micropterus salmoides). Microb Pathog. 2022 Dec;173(Pt A):105815. doi: 10.1016/j.micpath.2022.105815. Epub 2022 Oct 7. PMID: 36209969. 2: Periti P. Immunopharmacology of oral betalactams. J Chemother. 1998 Apr;10(2):91-6. doi: 10.1179/joc.1998.10.2.91. PMID: 9603632. 3: Toyoguchi T, Nakagawa Y. [Nephrotoxicity and drug interaction of vancomycin (2)]. Nihon Yakurigaku Zasshi. 1996 May;107(5):225-35. Japanese. doi: 10.1254/fpj.107.225. PMID: 8690304. 4: Araki A, Sendo F. Reduced anti-Pseudomonas aeruginosa activity of a cephalosporin, cefodizime, in rats whose neutrophils were selectively depleted by a monoclonal antibody. Microbiol Immunol. 1996;40(5):333-8. doi: 10.1111/j.1348-0421.1996.tb01076.x. PMID: 8999285. 5: Ueta E, Yoneda K, Yamamoto T, Osaki T. Upregulatory effects of cefpimizole natrium on human leukocytes. Int J Immunopharmacol. 1992 Jul;14(5):877-85. doi: 10.1016/0192-0561(92)90087-2. PMID: 1324894. 6: Nagano T, Ueno T, Mukai K, Yano S. [Case posing a therapeutic problem due to gastrointestinal hemorrhage caused by a factor VIII inhibitor following antibiotic administration]. Nihon Naika Gakkai Zasshi. 1991 Apr 10;80(4):619-20. Japanese. PMID: 1905741. 7: Ito K, Hayasaki M, Tamaya T. Pharmacokinetics of cephem antibiotics in exudate of pelvic retroperitoneal space after radical hysterectomy and pelvic lymphadenectomy. Antimicrob Agents Chemother. 1990 Jun;34(6):1160-4. doi: 10.1128/AAC.34.6.1160. PMID: 2393276; PMCID: PMC171777. 8: Oishi K, Matsumoto K, Yamamoto M, Morito T, Yoshida T. Stimulatory effect of cefodizime on macrophage-mediated phagocytosis. J Antibiot (Tokyo). 1989 Jun;42(6):989-92. doi: 10.7164/antibiotics.42.989. PMID: 2737956. 9: Raad II, Sherertz RJ, Loveless MO, Carillo C, O'Connor RP, Miller M, Mostow SR. Comparison of cefpimizole with cefotaxime and penicillin G for treatment of uncomplicated gonorrhea. Sex Transm Dis. 1988 Apr-Jun;15(2):73-7. doi: 10.1097/00007435-198804000-00001. PMID: 3041630. 10: Sato K, Saito H, Tomioka H. [In vitro and in vivo antimycobacterial activities of cefpimizole (AC-1370) and its effect on oxygen metabolism of host macrophages]. Kekkaku. 1988 Jan;63(1):19-25. Japanese. PMID: 3361739. 11: Koga H. High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1987 Dec;31(12):1904-8. doi: 10.1128/AAC.31.12.1904. PMID: 3439800; PMCID: PMC175825. 12: Novak E, Lakings DB, Paxton LM. Tolerance and disposition of cefpimizole in normal human volunteers after intramuscular administration. Antimicrob Agents Chemother. 1987 Nov;31(11):1706-10. doi: 10.1128/AAC.31.11.1706. PMID: 3435119; PMCID: PMC175025. 13: Hara K, Shimada J. [New antimicrobial agent series XXI: Cefpimizole]. Jpn J Antibiot. 1987 Jun;40(6):1108-22. Japanese. PMID: 3312705. 14: Friis JM, Lakings DB. High-performance liquid chromatographic method for the determination of cefpimizole in tissue. J Chromatogr. 1986 Oct 31;382:399-404. doi: 10.1016/s0378-4347(00)83551-3. PMID: 3782412. 15: Sandberg ET, Pegram PS, Roddy RE, Handsfield HH, Hampton KD, Shafran KM, Hook EW 3rd. Dose ranging study of cefpimizole (U-63196E) for treatment of uncomplicated gonorrhea in men. Antimicrob Agents Chemother. 1986 May;29(5):849-51. doi: 10.1128/AAC.29.5.849. PMID: 3089142; PMCID: PMC284165. 16: Lakings DB, Novak E, Friis JM, Lunan CM, Paxton LM. Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration. Antimicrob Agents Chemother. 1986 Feb;29(2):271-7. doi: 10.1128/AAC.29.2.271. PMID: 3717932; PMCID: PMC176389. 17: Kumar A, Kim CH. In vitro activity of cefpimizole sodium (U-63196E) and other antimicrobial agents against Haemophilus isolates from pediatric patients. Chemotherapy. 1986;32(2):126-30. doi: 10.1159/000238403. PMID: 3516592. 18: Obana Y, Nishino T, Tanino T. The therapeutic efficacy of AC-1370 against experimental infections in mice. J Antimicrob Chemother. 1985 Dec;16(6):727-34. doi: 10.1093/jac/16.6.727. PMID: 4093344. 19: LeFrock JL, Smith BR, Bihl J. Comparative in vitro evaluation of cefpimizole (U-63196E), a new antipseudomonal cephalosporin. Antimicrob Agents Chemother. 1985 Jul;28(1):133-7. doi: 10.1128/AAC.28.1.133. PMID: 3929676; PMCID: PMC176324. 20: Jones RN, Ayers LW, Gavan TL, Gerlach EH, Sommers HM. In vitro comparative antimicrobial activity of cefpimizole against clinical isolates from five medical centers. Antimicrob Agents Chemother. 1985 Jun;27(6):982-4. doi: 10.1128/AAC.27.6.982. PMID: 4026275; PMCID: PMC180204.